CWAN Reports 800+ AI Agents Now Available for Deployment Across $10 Trillion in Client Assets
5.11.2025 22:15:00 CET | Business Wire | Press Release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced the global deployment of CWAN GenAI, a newly-launched, embedded generative AI platform that can be deployed to transform investment management, risk management, reporting and operations across more than $10 trillion in institutional assets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105092732/en/
What sets CWAN GenAI apart from the experimental AI tools flooding the market is its production-ready integration. Unlike copilots or chat tools layered onto legacy systems, CWAN GenAI is fully integrated and deployed into production on CWAN’s front-to-back platform, enabling clients to work alongside AI as collaborative partners in their investment operations. The platform currently supports 800+ AI agents created by CWAN clients and internal teams, plus 20 highly trained domain-specific agents. These agents work in tandem with investment professionals, automating data-intensive tasks and augmenting human expertise across reconciliation, reporting, portfolio analysis, and client communications.
“We're witnessing the largest operational transformation in investment management since electronic trading,” said Sandeep Sahai, CEO at CWAN. “While the industry debates AI’s potential, our clients are already operating with autonomous intelligence that processes more data in a day than traditional systems handle in months. This is about fundamentally reimagining how institutional investment operations function in real-time.”
“The industry has been waiting for AI that can handle the complexity and scale of institutional operations,” said Souvik Das, Chief Technology Officer at CWAN. “We’ve engineered AI agents that can autonomously execute millions of tasks daily while maintaining the precision and auditability that institutions require. Our platform transforms operational efficiency, accelerates decision-making, and gives institutions confidence in leveraging AI across investment portfolios at enterprise scale.”
“CWAN’s agentic workflow architecture, built on AWS, demonstrates how modern investment platforms can scale while maintaining institutional-grade security and compliance standards,” said Brian Cassin, Capital Markets Leader at AWS. “By enabling real-time data processing, low-latency model orchestration, and encrypted model execution at institutional scale, CWAN can compress their data cycles (from 30 days to 24 hours), allowing their expanded customer base to identify issues and make decisions with speed and confidence.”
AI That’s Already Changing the Industry
The proof lies in the performance metrics emerging from CWAN’s client base, where CWAN GenAI is delivering measurable performance improvements:
- 90% reduction in manual reconciliation effort
- 80% faster regulatory and accounting report generation
- 50% faster financial close cycles
How Financial Professionals are Using CWAN GenAI
- Asset Managers use CWAN GenAI to automate variance analysis, fee calculations, and performance attribution, closing books faster and delivering error-free, audit-ready reports to regulators and clients the same day issues arise, strengthening trust and reducing restatement risk.
- Risk Analysts rely on CWAN GenAI to continuously scan concentration and counterparty risk across portfolios, running daily stress tests across asset classes and flagging emerging threats early so CIOs and risk committees can act before market shocks hit balance sheets.
- Operations Teams deploy CWAN GenAI for autonomous trade settlement, real-time cash management, and exception handling that resolves 90% of operational issues without human intervention.
Operational Intelligence at Work
CWAN GenAI operates as a 24/7 embedded operations layer within its unified platform—spanning accounting, trading, compliance, performance, and reporting—where its AI agents are ready to act with precision and transparency. When deployed by clients, the CWAN platform can:
- Reconcile portfolios autonomously, analyzing billions of data points daily.
- Generate audit-ready reports on demand via natural-language queries.
- Answer complex portfolio questions instantly using live accounting and trading data.
- Schedule workflow automations that continuously improve through feedback and learning.
The technology foundation enabling these results reflects a strategic partnership with cloud infrastructure leaders like AWS, whose robust platform powers CWAN GenAI with real-time data processing, low-latency model orchestration, and encrypted model execution, ensuring both performance and compliance at scale.
“CWAN GenAI’s combination of speed, accuracy, scalability and security—underpinned by AWS’s computational power and governance frameworks—empowers global financial institutions to deliver competitive advantage while meeting the rigorous regulatory requirements their clients demand,” added Cassin, AWS Capital Markets Leader.
CWAN’s comprehensive approach solves growing industry challenges for institutional investors who are under pressure from surging data volumes, tighter regulation, and relentless operational strain. While most competitors are still testing out pilots, CWAN is already executing at global scale, freeing thousands of hours weekly, transforming business models and enabling firms to shift from reactive operations to real-time intelligence so they can respond instantly to market moves, regulatory challenges and client needs.
About CWAN
Clearwater Analytics (NYSE: CWAN) is transforming investment management with the industry’s most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, CWAN’s single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, CWAN supports over $10 trillion in assets globally.Learn more at www.cwan.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251105092732/en/
Contacts
Media Contact:
Claudia Cahill, Head of Communications and PR | +1 208-433-1200 | press@cwan.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom